Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Exisulind (CP248) 通过激活蛋白激酶 G (PKG) 诱导细胞凋亡。 Exisulind 在实体瘤和血液癌细胞系中表现出抗肿瘤活性,并且是结肠癌、前列腺癌、膀胱癌、乳腺癌和肺癌啮齿动物模型中肿瘤生长的抑制剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 283 | 现货 | ||
5 mg | ¥ 663 | 现货 | ||
10 mg | ¥ 987 | 现货 | ||
25 mg | ¥ 1,990 | 现货 | ||
50 mg | ¥ 2,970 | 现货 | ||
100 mg | ¥ 4,280 | 现货 | ||
500 mg | ¥ 8,850 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 547 | 现货 |
产品描述 | Exisulind (CP248) induces apoptosis through the activation of protein kinase G (PKG). Exisulind exhibits antineoplastic activity in solid tumour and haematological cancer cell lines and is an inhibitor of tumour growth in rodent models of colon, prostate, bladder, mammary and lung cancer. |
体内活性 | The topical treatment with NO-Exisulind significantly reduced UVB-induced tumors in SKH-1 hairless mice. The tumors/tumor bearing mouse, the number of tumors/mouse and tumor volume/mouse decreased significantly (P < 0.05) as compared with vehicle-treated and UVB-irradiated positive controls. NO-Exisulind-treated animals showed reduced expression of proliferation markers, such as PCNA and cyclin D1. These mice also manifested increased expression of proapoptotic Bax and decreased expression of antiapoptotic Bcl2 with an increase in the number of TUNEL-positive cells in tumors. NO-Exisulind-treated tumors are less invasive and progress less efficiently from benign to malignant carcinomas[1]. |
别名 | Sulindac sulfone, CP248 |
分子量 | 372.41 |
分子式 | C20H17FO4S |
CAS No. | 59973-80-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (147.69 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.6852 mL | 13.4261 mL | 26.8521 mL | 67.1303 mL |
5 mM | 0.537 mL | 2.6852 mL | 5.3704 mL | 13.4261 mL | |
10 mM | 0.2685 mL | 1.3426 mL | 2.6852 mL | 6.713 mL | |
20 mM | 0.1343 mL | 0.6713 mL | 1.3426 mL | 3.3565 mL | |
50 mM | 0.0537 mL | 0.2685 mL | 0.537 mL | 1.3426 mL | |
100 mM | 0.0269 mL | 0.1343 mL | 0.2685 mL | 0.6713 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Exisulind 59973-80-7 Apoptosis Tyrosine Kinase/Adaptors PKA Sulindac sulfone CP 248 CP248 CP-248 Inhibitor inhibitor inhibit